 Home > Medical News > Latest Medical News > 2 Qilu Class 1 biological drugs are coming!

2 Qilu Class 1 biological drugs are coming!

 Last Update: 2021-10-10
 Source: Internet
 Author: User

Tags

new johnsonville tn

anti histone antibody

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

After the first evaluation of the anti-tumor drug hydroxyurea tablets, Qilu Pharmaceutical's oncology innovative drug pipeline also ushered in good news
.

On September 28, CDE's official website showed that Qilu Pharmaceutical's QLF32004 and QLP31907 injections for class 1 biological drug injections have obtained the implied license of clinical trials and are intended to be used for the treatment of advanced malignant solid tumors and B-cell malignant tumors

Class 1 biological drug injection QLF32004 is intended for the treatment of advanced malignant solid tumors, and QLP31907 injection is intended for the treatment of B-cell malignant tumors
.

Anti-tumor drugs are currently a hot field of research and development by domestic and foreign pharmaceutical companies, and their market scale has continued to rise
.

According to data from Meinenet, in 2020, the sales of terminal anti-tumor drugs in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 100 billion yuan, an increase of 9.

Sales of terminal anti-tumor drugs in public medical institutions in China (unit: ten thousand yuan)

Source: Mi Nei.
com, China's public medical institutions terminal competition pattern

Since the beginning of this year, Qilu Pharmaceutical has been approved clinically for 8 new class 1 drugs, including QLF32004 for injection, QLP31907 injection, QLF31907 for injection, QL1706 injection, QLS31905 for injection, QL1779 injection, VB4-845 injection and QLS31901 for injection
.

It is worth mentioning that the 8 Class 1 new drugs all focus on the field of tumor treatment
.

Qilu Pharmaceutical has been approved for clinical Class 1 new drugs since 2021

From the perspective of R&D progress, VB4-845 injection has started phase III clinical trials.
VB4-845 injection is an antibody-drug conjugate (ADC), which Qilu Pharmaceutical introduced from Sesen Bio in July 2020 for 35 million US dollars.
New cancer drugs
.

In addition, QLS31901 for injection, QLS31905 for injection, and QL1706 injection have all started phase I clinical trials

Data source: Minet database, CDE

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.